{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:28:38Z","timestamp":1787891318621,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"am","delay-in-days":320,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93020C00052"],"award-info":[{"award-number":["75N93020C00052"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jconrel.2024.11.023","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T22:17:37Z","timestamp":1731795457000},"page":"81-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability"],"prefix":"10.1016","volume":"377","author":[{"given":"Gaurav K.","family":"Gulati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian C.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"MacMillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibbu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse H.","family":"Erasmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Davie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Avril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit P.","family":"Khandhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.11.023_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2022-009010","article-title":"COVID-19 vaccine wastage in the midst of vaccine inequity: causes, types and practical steps","volume":"7","author":"Lazarus","year":"2022","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.608460","article-title":"RNA vaccines: a suitable platform for tackling emerging pandemics?","volume":"11","author":"Sandbrink","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0025","author":"Guarascio"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101262","article-title":"Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial","volume":"44","author":"Pollock","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0040","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41541-022-00590-x","article-title":"A phase I\/II randomized, double-blinded, placebo-controlled trial of a self-amplifying Covid-19 mRNA vaccine","volume":"7","author":"Low","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0045","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","volume":"29","author":"de Alwis","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0050","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ymthe.2022.01.001","article-title":"A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models","volume":"30","author":"Maruggi","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0055","author":"Roy"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0060","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.ymthe.2023.06.017","article-title":"A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation","volume":"31","author":"Kimura","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0065","series-title":"Presentation 5 & 20 dose\/vial","author":"Lyophilized mRNA vaccine for Injection (COVID-19)","year":"2018"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-02955-2","article-title":"An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2\/3 randomized trial","volume":"30","author":"Saraf","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41541-023-00799-4","article-title":"Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine","volume":"9","author":"MacMillen","year":"2024","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0080","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.omtm.2020.06.011","article-title":"Intramuscular delivery of replicon RNA encoding ZIKV-117 human monoclonal antibody protects against Zika Virus infection","volume":"18","author":"Erasmus","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104196","article-title":"Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in na\u00efve hamsters compared to ancestral vaccine","volume":"83","author":"Hawman","year":"2022","journal-title":"eBioMedicine"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2147\/IJN.S123062","article-title":"Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization","volume":"12","author":"Ball","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.11.023_bb0095","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0100","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","article-title":"A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery","volume":"25","author":"Gerhardt","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2024.11.023_bb0105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An Alphavirus- derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924007673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924007673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:28:06Z","timestamp":1734625686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924007673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"alternative-id":["S0168365924007673"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.023","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}